At the frontier of brain tumor research, we must leave no stone unturned

In our latest Special Report, Ali Hansford, head of social policy at the Association of the British Pharmaceutical Industry (ABPI), discusses the UK government's plans to invest £20 million ($27 million) more into the research, diagnosis and development of brain tumor treatments. She reflects on the work of pharma globally in this field.

In light of the government investment, we need to talk more about how we are going to find the next blockbuster treatments for these devastating diseases.

Nearly 11,500 people are diagnosed with a brain tumor every year in the UK, with fewer than 15% surviving beyond 10 years1. This week’s announcement from the Department of Health and Social Care – following the death of Dame Tessa Jowell - that it would be doubling investment for brain cancer research to £40 million ($54 million) is a welcome commitment to helping achieve a goal that our industry shares: finding innovative new treatments and cures for these diseases.